Infection and inflammation are associated with hypertriglyceridemia, which is thought to be mediated by cytokines. Previous studies at our laboratory and others have shown that tumor necrosis factor acutely increases serum triglyceride levels primarily by stimulating hepatic lipid synthesis and secretion. The role of interleukin-1 (IL-1), a cytokine that is also secreted by stimulated macrophages and that has many actions that overlap those of tumor necrosis factor, has not been studied in depth. The present study demonstrates that IL-1, at doses similar to those that cause fever and anorexia and that stimulate adrenocorticotropic hormone secretion, rapidly increases serum triglyceride levels; this elevation persists for at least 17 hours. Serum cholesterol levels are not altered by IL-1. Neither is the clearance of triglyceride-rich lipoproteins affected by IL-1. However, hepatic triglyceride secretion, measured by the Triton WR-1339 technique, is increased in IL-1-treated animals. Accompanying this stimulation in hepatic lipid secretion is an increase in de novo fatty acid synthesis in the liver. IL-1 does not increase serum free fatty acid and glycerol levels, suggesting that IL-1 does not stimulate lipolysis in vivo. Additionally, inhibition of lipolysis does not prevent the increase in serum triglyceride levels, providing further evidence that lipolysis does not play a crucial role in the increased hepatic lipid synthesis and secretion induced by IL-1. In contrast, tumor necrosis factor increases lipolysis, which contributes to the increase in serum trigtycerides. That multiple cytokines rapidly elevate plasma triglyceride levels suggest that these changes in lipid metabolism may play an important role in the organism's response to infection and inflammation. (Arteriosclerosis and Thrombosis 1991;ll:495-500)
I nfection results in hypertriglyceridemia, which is primarily due to the accumulation of very low density lipoprotein (VLDL). 1 -5 Many of the metabolic responses to infection, including hyperlipidemia, are mediated by cytokines, 6 -8 and the cytokine, tumor necrosis factor (TNF), has been shown to rapidly increase serum triglyceride levels. 9 - 12 Studies have shown that TNF decreases the activity of lipo-protein lipase (LPL) in cultured fat cells 13 " 15 and in the epididymal fat pad of rats treated in vivo. 16 - 18 A decrease in adipose tissue LPL activity could produce hypertriglyceridemia by decreasing the clearance of triglyceride-rich lipoproteins. 10 Recent studies indicate that TNF increases serum triglyceride levels in rodents primarily by stimulating hepatic lipid secretion. First, TNF increases de novo hepatic lipogenesis before the increase in serum triglyceride levels. 9 Second, the increase in serum triglycerides precedes the decrease in LPL activity in the epididymal fat pad; in addition, little or no decrease is seen in LPL activity in several other sites of adipose tissue or muscle in vivo. 1617 In fact, LPL activity is increased in the postheparin plasma of TNF-treated animals. 16 Third, TNF is just as effective in increasing serum triglyceride levels in streptozotocin-diabetic rats in which adipose tissue LPL activity is markedly reduced secondary to diabetes 19 ; more importantly, no further decrease in adipose tissue LPL activity is seen after TNF treatment of diabetic animals. 19 TNF does stimulate hepatic lipid synthesis in diabetic animals. 19 Fourth, TNF treatment does not decrease the clearance of triglyceriderich lipoproteins from the circulation. 111819 Finally, total hepatic trigh/ceride secretion is increased in TNFtreated animals as measured by the Triton WR-1339 technique.
18^20 The TNF-induced increase in hepatic triglyceride production is a result of increased de novo fatty acid synthesis and reesterification of fatty acids derived from peripheral lipolysis. 21 The VLDL that is secreted in response to TNF has a normal lipid and protein composition. 11 Taken together, these observations indicate that TNF stimulation of hepatic triglyceride production is the major cause of the hyperlipidemia that follows TNF administration. Studies by others 10 have demonstrated a decreased disposition of dietary fat in adipose tissue in TNF-treated animals, suggesting that under some experimental conditions, the TNF inhibition of adipose tissue LPL may play a role in hypertriglyceridemia.
TNF is one of several cytokines that are released in response to infection and injury. 6 - 8 Cytokines have pleotropic actions, with many cytokines having similar metabolic effects. The two major cytokines released by stimulated macrophages are TNF and interleukin-1 (IL-1), and there is extensive but not complete overlap in the immunological properties of TNF and IL-1. 22 The aim of the present study was to examine the effect of IL-1 on lipid metabolism in the intact rat.
Methods

Materials
3 H 2 O (1 Ci/g) was purchased from ICN Radiochemicals (Irvine, Calif.) [26- 14 C]cholesterol, [ Ready-safe scintillation fluid was from Beckman (Beckman Instruments, Palo Alto, Calif.); and R-2-phenylisopropyl adenosine (PIA) was from Boehringer Mannheim (Mannheim, F.R.G.). Rat chow was purchased from Simonsen (Gilroy, Calif.) and consisted of approximately 24% protein, 6% fat, 6% ash, 3.5% fiber, and 60% complex carbohydrate, all derived from ground wheat, soybean meal, and rice bran. Other dietary components were purchased from ICN. Recombinant human IL-1-0 (112-269) had a specific activity of 5xlO 7 units/mg and was produced as described previously. 23 
Animal Procedures
Male Sprague-Dawley rats (=200 g) were purchased from Bantin and Kingman (Gilroy, Calif.). The animals were maintained in a reversed-lightcycle room (3 AM to 3 PM dark, 3 PM to 3 AM light) and were provided with rat chow and water ad libitum. Where indicated, the animals were fed a high-sucrose diet consisting of 20% vitamin-free casein, 4% salt (Hegstad, ICN), 76% sucrose, and 22 g/kg diet of vitamin mixture (ICN) for 3 days before the study.
Animals were injected via the tail vein with 1 ng IL-1 in 0.5 ml 0.9% saline or saline alone (control). After IL-1 or saline injection, food was withdrawn because IL-1 administration induces anorexia. 24 Where indicated, animals were injected subcutaneously with 0.15 mmol/kg PIA in 0.3 ml saline or an equal volume of saline alone (control) 30 minutes before IL-1 administration.
Lipogenesis
One hour after IL-1 administration, the animals were injected intraperitoneally with 50 mCi 3 H 2 O. One hour later, the animals were anesthetized and weighed and a blood specimen was obtained. The incorporation of 3 H 2 O into lipids in the liver was determined as described previously. 25 - 26 The validity of our methodology for measuring lipid synthesis has been demonstrated in earlier publications.
-26
Chylomicron Clearance Studies
Chylomicron clearance was determined as described previously.
19
- 21 Briefly, the mesenteric lymph duct was cannulated, and the rats were administered 100 /i,Ci [ 
Hepatic Triglyceride Secretion
Hepatic triglyceride secretion was determined as previously described 20 after administration of Triton WR-1339, a nonionic detergent that traps lipoproteins in the plasma and thereby allows determination of the rate of secretion of lipoproteins.
27
- 29 Rats were administered 1 ^.g IL-1 and 120 mg Triton WR-1339 in 0.9% saline intravenously at time zero. One and 2 hours later, a blood sample was obtained for determination of serum triglyceride levels. The increase in serum triglyceride levels between 1-2 hours is equivalent to the rate of secretion of triglyceride-containing lipoproteins.
Plasma Free Fatty Acid and Glycerol Levels
Blood for free fatty acid analysis was placed in iced, heparinized glass tubes within 30 seconds of sampling and centrifuged at l,000g at 4°C, and the plasma was separated. The free fatty acid content of the plasma was determined by a modification of the method of Ko and Royer, 30 as previously described. 31 To 1 ml plasma, 0.1 ml 30% HC1O 4 was added, and the plasma was centrifuged at 2,000 rpm for 10 minutes. The supernatant was adjusted to pH 9.5 with KOH, and after removal of the KC1O 4 by centrifugation at 2,000 rpm for 10 minutes, a 0.2-ml aliquot was used for enzymatic fluorometric determination of glycerol. 32 
Plasma Lipid Levels
Plasma triglyceride levels were measured using Sigma diagnostic kit No. 405 (Sigma Chemical Co., St. Louis, Mo.) after extraction with Dole's reagent. Plasma cholesterol levels were measured using Sigma diagnostic kit No. 351.
Statistics
Statistical differences were determined using a two-tailed Student's / test. Because of variations in the rates of lipid synthesis and secretion from month to month, only the animals that were studied simultaneously under identical conditions were compared.
Results
Serum Lipid Levels
The short-term effects of IL-1 administration on serum lipid levels are shown in Tables 1 and 2 . At 2 hours after IL-1 treatment, serum triglyceride levels increased 116% in chow-fed animals ( Table 1) . In contrast, IL-1 had no effect on serum cholesterol concentrations. In animals fed a sucrose diet, IL-1 administration also increased serum triglyceride levels 58% without altering serum cholesterol concentrations ( Table 2 ). The increase in serum triglyceride levels was still observed 17 hours after IL-1 administration in chow-fed animals (control [n=5], 33±3 mg/dl versus IL-1 [n=5], 55±9 mg/dl, p<0.05). However, unlike results with TNF, 9 -" IL-1 did not produce a late increase in serum cholesterol levels (control, 140±12 mg/dl versus IL-1, 154±16 mg/dl, p=NS). These results indicate that IL-1 administration rapidly increases serum triglyceride concentrations and that this increase persists for an extended period of time.
Chylomicron Clearance
To determine if the increase in serum triglyceride levels after EL-1 administration was due to changes in the clearance of triglyceride-rich lipoproteins, we next measured chylomicron clearance. The clearance of chylomicrons labeled in triglyceride or cholesterol was similar in control and IL-1-treated animals (triglyceride XVi in control, 2.3±0.2 minutes versus IL-1, 2.4 ±0.25 minutes, p=NS; cholesterol Wi in control, 4.5±0.55 minutes versus IL-1, 4.5±0.03 minutes, p=NS). These results indicated that the increase in serum triglyceride levels in IL-1-treated animals was not due to an IL-1-induced alteration in the clearance of triglyceride-rich lipoproteins.
Triglyceride Secretion
To determine if IL-1 administration acutely stimulated hepatic lipoprotein secretion, we next measured the rate of increase in serum triglyceride levels from 1 to 2 hours after the simultaneous administration of IL-1 and Triton WR-1339. To minimize the contribution from the intestine, these Rats were fed a high-sucrose diet for 3 days and on the morning of the study were administered 1 /ig interleukin-1 (IL-1) or saline (control) i.v. One hour later, 50 mCi 3 H 2 O i.p. was administered. One hour after ^O administration, animals were killed, blood was obtained, and incorporation of ^O into cholesterol and fatty acids in the liver was determined as described in "Methods." Values are mean±SEM. N=15 for serum triglyceride and cholesterol, N=15-2S for plasma FFA and glycerol, and N=W for -^O incorporation.
FFA, free fatty acids. studies were performed in animals fed a fat-free sucrose diet. IL-1 increased triglyceride secretion by 75% (Figure 1 ). These results suggested that IL-1 acutely stimulated the hepatic secretion of triglyceride-containing lipoproteins.
Lipogenesis
De novo fatty acid synthesis was assayed by the incorporation of 3 H 2 O into lipids in the liver during a period of 1-2 hours after IL-1 administration. In chow-fed animals, de novo hepatic fatty acid synthesis was increased 66% in the IL-1 group (Table 1) . In contrast, cholesterol synthesis was not altered by IL-1 administration. As shown by other investigators, 33 ' 34 baseline fatty acid synthesis in the liver is markedly increased in animals fed a high-sucrose diet. Nevertheless, as shown in Table 2 , the administration of IL-1 acutely increased fatty acid synthesis 102% in sucrose-fed animals without altering cholesterol synthesis. These results indicate that IL-1 acutely stimulates de novo hepatic fatty acid synthesis.
Serum Free Fatty Acid and Glycerol Levels
In chow-fed animals, IL-1 administration did not affect serum free fatty acid levels (Table 1) . Serum glycerol levels were modestly decreased in IL-1-treated animals (Table 1 ). In sucrose-fed animals, IL-1 did not alter either serum free fatty acid or glycerol concentrations (Table 2) . These results suggested that in contrast to TNI To further elucidate the potential role of lipolysis in the IL-1-induced increase in serum triglyceride levels, we employed the drug PIA, which has been shown to inhibit adipose tissue lipolysis without affecting de novo fatty acid synthesis in the liver. In chow-fed animals, IL-1 alone increased serum triglyceride levels 2.87-fold over controls, whereas IL-1 plus PIA increased serum triglyceride levels 2.60 -fold over PIA-treated controls. Similarly, in sucrose-fed animals, IL-1 alone increased serum triglyceride levels 2.02-fold, whereas IL-1 plus PIA increased serum triglyceride levels 2.18-fold. These results together with the absence of an increase in serum free fatty acid and glycerol levels suggested that increased lipolysis was not essential for the IL-1 stimulation of hepatic triglyceride production and elevation of serum triglyceride levels.
Discussion
While the effects of TNF on lipid metabolism have been extensively investigated, few studies have focused on the effects of IL-1 on lipid metabolism. In cultured adipocytes, IL-1 inhibits LPL activity and lipogenesis. 37 - 38 In intact animals, high doses of IL-1 have been shown to increase serum triglyceride levels, 39 whereas in diabetic mice, IL-1 treatment decreases serum triglyceride levels. 40 Previous studies with mice at our laboratory have demonstrated that IL-1 administration rapidly increases de novo fatty acid synthesis in the liver of normal mice. 41 In contrast, Argiles et al 39 did not observe an effect of IL-1 on hepatic lipogenesis in rats. However, in our studies, the dose of IL-1 that increased hepatic fatty acid synthesis (40 ng/mouse) was similar to that which causes fever, 23 whereas in the study of Argiles et al, high doses of IL-1 were employed (20 /ng/rat). Additionally, in the studies of Argiles et al, the animals were given oral glucose before measurement of lipid synthesis, which could stimulate lipid synthesis and perhaps blunt the differences between control and IL-1-treated animals.
The present study demonstrates that administration of IL-1 at modest doses similar to those that cause fever and anorexia and that stimulate adrenocorticotropic hormone secretion 23   -42   - 44 rapidly increases serum triglyceride levels in both chow-fed and sucTOse-fed rats. This elevation in triglycerides persists for at least 17 hours. In conjunction with this increase in serum triglyceride levels, hepatic triglyceride secretion is increased. Accompanying this increase in hepatic lipid secretion is an increase in de novo fatty acid synthesis in the liver, which is seen in animals fed either a chow or a high-sucrose diet. Although IL-1 decreases LPL activity in cultured fat cells, 3738 in our experiments such changes are unlikely to play a significant role in hypertriglyceridemia because the clearance of triglyceriderich lipoproteins is not altered by IL-1 in the intact animal. However, in other studies 39 where higher doses of IL-1 were administered, there was a decreased disposition of dietary lipid in adipose tissue, suggesting that inhibition of adipose tissue LPL may play a role in hypertriglyceridemia. It is likely that cytokines can affect many different aspects of lipid metabolism, and which effects predominate may depend on the cytokine, the dose studied, and the environment of the animal.
While in our studies TNF and IL-1 share many effects on Iipid metabolism, it is worth noting that there are several differences. First, TNF leads to an increase in serum cholesterol levels after several hours, 911 which is accounted for by an increased low density lipoprotein (LDL) level. 11 The mechanism by which TNF increases serum cholesterol and LDL levels is unknown. In contrast, IL-1 has no effect on serum cholesterol levels. The fact that both TNF and IL-1 increase serum triglyceride levels but that only TNF increases serum cholesterol levels suggests that the increase in serum cholesterol is not simply the processing of triglyceride-rich lipoproteins to cholesterol-enriched lipoproteins. Second, TNF administration results in an increase in serum free fatty acid and glycerol levels, indicative of increased lipolysis in chow-fed rats. 21 - 35 In contrast, IL-1 does not increase serum free fatty acid or glycerol levels, suggesting that IL-1 does not stimulate lipolysis. Others 39 have also shown no effect on serum free fatty acid levels after IL-1 administration. Third, when the lipolysis induced by TNF in chow-fed rats is blocked with the drug PIA, the TNF-induced increase in serum triglyceride levels is blunted. 21 This suggests that in TNF-treated animals, the transport of fatty acids from adipose tissue to the liver is an important source of the fatty acids required for triglyceride synthesis. In contrast, in IL-1 treated animals, PIA does not affect the increase in serum triglyceride levels, suggesting that lipolysis does not play a crucial role in the increased hepatic Iipid synthesis and secretion induced by IL-1. This situation is analogous to our findings in sucrose-fed animals, where TNF does not increase lipolysis, and peripheral free fatty acids do not significantly contribute to the TNF-induced increase in serum triglycerides. 21 Thus, the fatty acids required for triglyceride formation are derived primarily from de novo fatty acid synthesis by the liver or the utilization of stored Iipid in hepatocytes in sucrose-fed, TNF-treated animals and in IL-1-treated animals regardless of diet. It is unlikely that dietary fatty acids contribute significantly to this effect because the increases in serum triglyceride and hepatic triglyceride secretion are observed in animals fed a fat-free diet.
Whether TNF or IL-1 directly stimulates hepatic Iipid synthesis and secretion has not been definitively answered. We have recently demonstrated that both TNF and IL-1 stimulate Iipid synthesis and secretion in HepG2 cells in culture, suggesting that these cytokines can directly affect the liver (C. Grunfeld, C.A. Dinarello, and K.R. Feingold, unpublished observations).
That several cytokines elevate plasma triglyceride levels suggests that these changes in Iipid metabolism may play an important role in the organism's response to infection and inflammation. Although the precise role of hyperlipidemia is not yet known, recent studies have demonstrated that triglyceriderich lipoproteins bind endotoxin and protect animals from the mortality that normally occurs after endotoxin administration. 45 In addition, other studies have shown that lipoproteins neutralize viruses, 4647 and therefore, cytokine-induced increases in Iipid levels may be beneficial in viral illness as well. Thus, it is possible that the alterations in hepatic lipid metabolism induced by cytokines are a component of the host-defense response.
